Cambridge, MA – January 9, 2023 – OncoPep, Inc. is proud to be a presenter at this year’s Biotech Showcase January 9-11 in San Francisco. The company will be sending members of its executive team including Chief Operating Officer...
Cambridge, MA – June 14, 2022 – OncoPep, Inc. has named Sanghyuck Nam Chief Financial Officer effective May 11th. In addition to his responsibilities for OncoPep’s financial controls and planning, Nam will be integral to continuing...
Cambridge, MA - June 9, 2022 - OncoPep, Inc. is proud to be a participant at this year’s BIO International Convention 2022 conference June 13-16 in San Diego CA. The company will be sending members of its executive team including CEO...
Cambridge, MA - May 17, 2022 - OncoPep, Inc. has named Dr. Victor Moyo Chief Medical Officer effective May 9th. As CMO, Moyo will provide strategic clinical leadership to ensure delivery of OncoPep’s efforts to develop transformative...
Michael D. Krepps. A poster presenting the final results of an investigator-sponsored study led by Dr. Steven J. Isakoff, MD, Ph.D. (Massachusetts General Hospital) titled: A Phase 1b study of PVX-410 Vaccine in Combination with...
Cambridge, MA - December 09, 2021 – OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera Science and Kukje Pharma with participation from SX Company and...
Cambridge, MA – November 09, 2021 – OncoPep, Inc. today announced it is expanding its Scientific Advisory Board with the addition of Carl Novina, MD, Ph.D. As the leader and founder of the Dana‐Farber/Harvard Cancer Institute’s...
BOSTON – October 15, 2020 – OncoPep, Inc. today announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the development of an autologous multi-tumor antigen adoptive T cell therapy for the treatment...
BOSTON – August 8, 2018 – OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating the safety and tolerability of PVX-410, an investigational multi-peptide cancer vaccine, for patients with smoldering...
BOSTON – February 22, 2017 -- OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating its investigational vaccine product PVX-410for the treatment of patients with metastatic triple negative breast cancer...